Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

that of nocturia which may result from other conditions such as overactive bladder.

About VA111913 and dysmenorrhoea:

VA111913 is an oral small molecule drug candidate in Phase I clinical development for prevention and treatment of dysmenorrhoea, a condition characterized by abnormal contractions of the uterus during menstruation causing severe pain. VA111913 acts by blocking vasopressin 1a receptors in smooth muscle in the uterus wall, which in response to elevated vasopressin levels leads to dysmenorrhoea. VA111913 has demonstrated in preclinical trials it can normalise smooth muscle contraction thereby offering the potential for it to be the first licensed drug that directly targets the cause of this condition in the uterus.

A Phase I trial with VA111913 is underway and expected to report during H1 2009, with Phase II proof of concept studies expected to start in H2 2009, involving up to 150 patients and completing in H2 2010.

Dysmenorrhoea affects a large number of women for whom there are currently no targeted therapies; treatments that are in common use however include over-the-counter painkillers (e.g. naproxen or ibuprofen) or oral contraceptives used 'off-label'. It is estimated that the market opportunity for a targeted drug for the prophylaxis and treatment of dysmenorrhoea is approximately US$1 billion per year.

    Contact details:


    Vantia Therapeutics

    Dr Jim Phillips, CEO              +44(0)238-076-3433
    ir@vantiatherapeutics.com         +44(0)7515-397176


    Citigate Dewe Rogerson
    Chris Gardner / Mark Swallow / Helena Galilee
    +44(0)207-638-9571
    chris.gardner@citigatedr.co.uk / mark.swallow@citigatedr.co.uk /
    helena.galilee@citigatedr.c
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 Follow ... level of each type of cholesterol carrier or lipoprotein ... presence of excessive cholesterol levels in the body, especially ... condition to heart attack and other cardiovascular disorders. Cardiovascular ... therefore testing for cholesterol levels on a regular basis, ...
(Date:9/30/2014)... 30, 2014 OriginOil Inc. (OTC/QB: OOIL), ... process to clean up large quantities of water, announced ... Eckelberry reported on the launch of the company's CLEAN-FRACâ„¢ ... provided by partner STW Resources . , Immediately ... per day (bpd) and achieved a 99.8% reduction in ...
(Date:9/30/2014)... The overall research objective was to ... and use. Most researchers outsource NGS technologies; however, ... within the next 12 months. Data accuracy and ... sequencing instruments. Disease-related research is the dominant use ... to surge, with half of the respondents planning ...
(Date:9/30/2014)... 30, 2014 On September 11, Pharma IQ ... in anticipation of a session that he will lead on ... scheduled for February 17-18, 2015 in London. In the ... asked Dr. Sherley to respond to several questions on the ... to evaluating stem cell toxicity, and future trends in the ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Global Next-generation Sequencing Trends 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4
... with the 20th Anniversary of the Draper Prize, Draper Laboratory, in ... new website for students and adults to learn about the impact ... accomplishments of the 32 engineers who have been awarded "Engineering,s Nobel" ... ...
... 12 Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: ... and six-month periods ended December 31, 2008. Revenues for ... compared to $3.7 million for the second quarter of ... for the three months ended December 31, 2008 compared ...
... Calif., Feb. 12 iZumi Bio, Inc., announced,today the ... and a,member of the company,s Board of Directors. ... Inc. which merged with Transcept Pharmaceuticals,Inc. in January 2009. ... , iZumi Bio is focused ...
Cached Biology Technology:New Educational Website Celebrates the Accomplishments of Engineers 2Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 2Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 3Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 4iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer 2
(Date:9/30/2014)... Winners of The Economist,s prestigious Innovation awards 2014 will ... at the JW Marriott Hong Kong on Friday, October 10 th ... experiences and the lessons those hold for others. The awards, which ... past decade, will be presented at a ceremony in ... be the first time the ceremony has come to ...
(Date:9/29/2014)... a NASA story from 2009, "human activities in this area ... issue. Palm oil is increasingly grown for use as a ... processed foods. It has become the most widely produced edible ... years to surpass that of soybean oil. , The environmental ... be cleared to grow the crop, and the preferred method ...
(Date:9/29/2014)... Mountain pine beetles get a bad rap, and understandably ... trees over tens of millions of acres in the ... , But contrary to popular belief, these pests may ... those that have recently swept through the region. Instead, ... ecological severity of fires than these bark-boring beetles. , ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... developed a new technique for creating human embryonic stem ... cells. The fusion causes the adult cells to undergo ... developmental characteristics of human embryonic stem cells. , ... nuclear transfer (SCNT), a method that is currently used ...
... Remains of photosynthesizing microbes in prehistoric rocks suggest Earth ... techniques to previously unexamined rock formations has turned up ... decades-long scientific argument. , The study appears in the ... Olcott, a Ph.D. student of earth sciences in the ...
... with mice, researchers have found that nicotine triggers ... as heroin their addictively rewarding properties--including associating an ... nicotine does not directly activate the brain's opiate ... in the brain. , The researchers, led by ...
Cached Biology News:Researchers devise new technique for creating human stem cells 2Researchers devise new technique for creating human stem cells 3Researchers devise new technique for creating human stem cells 4Study casts doubt on 'Snowball Earth' theory 2Nicotine triggers the same brain reward circuitry as opiates 2
... EZ-Spread Plating Beads Sterile plating in ... glass rods and potentially hazardous ethanol flaming, ... choices of ready-to-use sterile packaging: dispenser bottle for ... plating, Fastest and easiest way to ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... a regulated environment, Pipette Tracker Pro ... that automates gravimetric pipette calibration and ... meets todays regulatory compliance requirements. Pipette ... that includes a full security implementation, ...
... the yolk protein Vtg in plasma from juvenile ... biomarker for endocrine disrupting chemicals (EDCs) with estrogenic ... an accepted screening test for the estrogenic effects ... EIA kit is a double-antibody immunometric (sandwich) EIA ...
Biology Products: